9 Meters Biopharma

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.

New York Mortgage Trust, Inc. is a real estate investment trust, which engages in the acquisition, investment, finance, and management of mortgage-related single-family and multi-family residential assets. Its investment portfolio includes credit sensitive single-family and multi-family assets. The company was founded on September 26, 2003 and is headquartered in New York, NY.

RALEIGH, NC / ACCESSWIRE / March 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appointed Michael Rice to its board of directors. Mr. Rice is the president and co-founder of LifeSci Advisors, a life sciences investor relations consultancy, and the co-founder of LifeSci Capital, a research-driven investment bank.

9 Meters Biopharma, Inc. Appoints Michael Rice to Board of Directors

9 Meters Biopharma (NMTR) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

9 Meters Biopharma (NMTR) is Overbought: Is A Drop Coming?

Cenovus Energy

Century Casinos

Viveve Medical

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Huge Upside Potential in 5 Stocks Trading Under $10

NMTR stock is on the move Wednesday. Here's what you should know about 9 Meters Biopharma, which specializes in GI conditions.

NMTR Stock: 12 Things for Investors to Know About 9 Meters Biopharma

Larazotide, a novel tight junction modulator, has shown positive effect in multiple lung models of acute respiratory distress, acute lung injury, and pulmonary fibrosis with potential effects in COVID-19 patients EBRIS will advance larazotide into an Australian Investigational New Drug Phase 1 study expected to begin in 2021 RALEIGH, NC and SALERNO, ITALY / ACCESSWIRE / December 21, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced a collaboration with the European Biomedical Research Institute of Salerno (EBRIS), to advance to a study in order to evaluate the safety and tolerability of larazotide when delivered to lung tissue in healthy volunteers. Larazotide, a first-in-class tight junction modulator, is hypothesized to act on lung endothelial cells.

9 Meters Biopharma Announces Agreement with the European Biomedical Research Institute of Salerno (EBRIS) to Continue Evaluation of Larazotide for COVID-19 Respiratory Complications

9 Meters Biopharma (NMTR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

9 Meters Biopharma (NMTR) Catches Eye: Stock Jumps 7.8%

9 Meters Biopharma (NMTR) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

9 Meters Biopharma (NMTR) in Focus: Stock Moves 5.8% Higher

Shares of 9 Meters Biopharma Inc (NASDAQ: NMTR) were ripping higher following a bullish initiation by Brookline Capital Markets.

Why This 9 Meters Biopharma Analyst Sees 800% Upside Ahead

NEW YORK, July 13, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of 9 Meters Biopharma, Inc. (NASDAQ: NMTR). If you...

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating 9 Meters Biopharma, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

9 Meters Biopharma Inc. (NASDAQ: NMTR) may not be a household name right now, but one brokerage firm sees huge potential upside.

News for 9 Meters Biopharma Stock (NMTR)